Benign Prostatic Hyperplasia (BPH) Drugs Market Report

China Benign Prostatic Hyperplasia (BPH) Drugs Industry Market Research Report 2023-2029

  • POSTDATE：Sep 09, 2023
  • PAGES：210
  • REPORT CODE：GMM1784692
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

    The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.

    This report elaborates on the current development of the Benign Prostatic Hyperplasia (BPH) Drugs industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Bayer HealthCare

    • ADC Therapeutics

    • Astellas Pharma

    • Foresee Pharmaceuticals

    • Valeant Pharmaceuticals

    • Eli Lilly

    • GlaxoSmithKline

    • Sanofi

    • Bristol-Myers Squibb

    By Type:

    • 5-Alpha-Reductase Inhibitors

    • Alpha-Blocker

    • Phosphodiesterase Type-5 Inhibitors

    By Application:

    • Women

    • Men

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Overview 2018-2029

    • 1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Industry Development Overview

    • 1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Industry Development History

    • 1.3 China Benign Prostatic Hyperplasia (BPH) Drugs Industry Market Size (2018-2029)

    • 1.4 China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis by Type from Production Side

      • 1.4.1 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume, Production Value and Growth Rate of 5-Alpha-Reductase Inhibitors (2018-2029)

      • 1.4.2 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume, Production Value and Growth Rate of Alpha-Blocker (2018-2029)

      • 1.4.3 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume, Production Value and Growth Rate of Phosphodiesterase Type-5 Inhibitors (2018-2029)

    • 1.5 China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis by Application from Consumption End

      • 1.5.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate of Women (2018-2029)

      • 1.5.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate of Men (2018-2029)

    • 1.6 China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis by Region

      • 1.6.1 North China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    Chapter 2 China Benign Prostatic Hyperplasia (BPH) Drugs Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Competition Analysis in 2023

      • 2.2.3 China Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Benign Prostatic Hyperplasia (BPH) Drugs Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Benign Prostatic Hyperplasia (BPH) Drugs Industry Development

    Chapter 3 Benign Prostatic Hyperplasia (BPH) DrugsIndustry Chain Analysis

    • 3.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain

    • 3.2 Benign Prostatic Hyperplasia (BPH) Drugs Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Benign Prostatic Hyperplasia (BPH) Drugs Market

    • 3.3 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Benign Prostatic Hyperplasia (BPH) Drugs Market

    Chapter 4 China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 4.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Benign Prostatic Hyperplasia (BPH) Drugs Total Production Volume and Growth Rate from Production Side

    • 4.5 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Growth Rate, by Type

      • 4.5.1 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Growth Rate of 5-Alpha-Reductase Inhibitors

      • 4.5.2 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Growth Rate of Alpha-Blocker

      • 4.5.3 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Growth Rate of Phosphodiesterase Type-5 Inhibitors

    Chapter 5 China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Benign Prostatic Hyperplasia (BPH) Drugs Total Market Size and Growth Rate from Consumption End

    • 5.5 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate, by Application

      • 5.5.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Women

      • 5.5.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Men

    Chapter 6 China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Region

    • 6.1 China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Production Value, by Region

    • 6.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Sales Value, by Region

    Chapter 7 North China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis

    • 7.1 North China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 7.2 North China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    Chapter 8 Central China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis

    • 8.1 Central China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 8.2 Central China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    Chapter 9 South China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis

    • 9.1 South China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 9.2 South China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    Chapter 10 East China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis

    • 10.1 East China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 10.2 East China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    Chapter 11 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis

    • 11.1 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 11.2 Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    Chapter 12 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis

    • 12.1 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 12.2 Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    Chapter 13 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis

    • 13.1 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type

    • 13.2 Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Bayer HealthCare

        • 14.1.1 Bayer HealthCare Company Profile

        • 14.1.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 ADC Therapeutics

        • 14.2.1 ADC Therapeutics Company Profile

        • 14.2.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Astellas Pharma

        • 14.3.1 Astellas Pharma Company Profile

        • 14.3.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Foresee Pharmaceuticals

        • 14.4.1 Foresee Pharmaceuticals Company Profile

        • 14.4.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Valeant Pharmaceuticals

        • 14.5.1 Valeant Pharmaceuticals Company Profile

        • 14.5.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Eli Lilly

        • 14.6.1 Eli Lilly Company Profile

        • 14.6.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 GlaxoSmithKline

        • 14.7.1 GlaxoSmithKline Company Profile

        • 14.7.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Sanofi

        • 14.8.1 Sanofi Company Profile

        • 14.8.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Bristol-Myers Squibb

        • 14.9.1 Bristol-Myers Squibb Company Profile

        • 14.9.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Market Performance

        • 14.9.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Research Conclusions

    • 15.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Industry Market Size (2018-2029)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume, Production Value and Growth Rate of 5-Alpha-Reductase Inhibitors (2018-2029)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume, Production Value and Growth Rate of Alpha-Blocker (2018-2029)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume, Production Value and Growth Rate of Phosphodiesterase Type-5 Inhibitors (2018-2029)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate of Women (2018-2029)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate of Men (2018-2029)

    • Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate from 2018-2029

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2018

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2023

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Growth Rate of 5-Alpha-Reductase Inhibitors (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Growth Rate of Alpha-Blocker (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume and Growth Rate of Phosphodiesterase Type-5 Inhibitors (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2018

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2023

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Total Market Size and Growth Rate from Consumption End

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Women (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Men (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Region (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Region (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Region (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Production Value by Region (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Production Value Share by Region (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Value Share by Region (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Region (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Region (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Region (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Region (2018-2023)

    • Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Region (2018-2023)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Region (2018-2023)

    • Table North China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Type (2018-2023)

    • Table North China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Table North China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2018-2023)

    • Table North China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure North China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Type (2018-2023)

    • Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2018-2023)

    • Table Central China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Central China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Table South China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Type (2018-2023)

    • Table South China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Table South China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2018-2023)

    • Table South China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure South China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Table East China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Type (2018-2023)

    • Table East China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Table East China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2018-2023)

    • Table East China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure East China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Type (2018-2023)

    • Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2018-2023)

    • Table Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Type (2018-2023)

    • Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2018-2023)

    • Table Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume by Type (2018-2023)

    • Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Production Volume Share by Type (2018-2023)

    • Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2018-2023)

    • Table Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2018-2023)

    • Table Bayer HealthCare Company Profile

    • Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table ADC Therapeutics Company Profile

    • Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Astellas Pharma Company Profile

    • Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Foresee Pharmaceuticals Company Profile

    • Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Valeant Pharmaceuticals Company Profile

    • Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Eli Lilly Company Profile

    • Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline Company Profile

    • Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Sanofi Company Profile

    • Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)

    • Table Bristol-Myers Squibb Company Profile

    • Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US